(thirdQuint)ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection.

 This is an open-label extension of Study SERES-012.

 Subjects who had a CDI recurrence in Study SERES-012 within 8 weeks of receipt of study drug, have responded to a course of standard of care (SOC) antibiotic treatment, and who have completed their SERES-012 Week 8 visit will receive an oral dose of SER-109.

 A treatment regimen of SER-109 is defined as an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days.

 Approximately 100 eligible subjects with recurrent CDI disease from Study SERES-012 are expected to enroll.

 Screening for this study will begin at the Week 8 Visit of Study SERES-012.

.

 ECOSPOR IV: An Open-Label Extension of Study SERES 012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection@highlight

Subjects who had a CDI recurrence in Study SERES-012 within 8 weeks of receipt of study drug will receive an oral dose of SER-109 in 4 capsules once daily for 3 consecutive days.

 The purpose of this study is to assess safety and efficacy of SER-109 in reducing recurrence of Clostridium difficile infection (CDI) in adults who had a CDI recurrence within 8 weeks after receipt of SER-109 or Placebo in Study SERES-012.

